High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017